Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07259317 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 16 → 20 locations Eligibility criteria expanded, about 31 words Show 1 more changeShow less
    • Eligibility criteria expanded, about 31 words
  2. Study sites: 15 to 16v8
  3. Study sites: 14 to 15v7
  4. Primary endpoint(s) modified Primary and study completion pushed from Jul 2027 to Sep 2027 · Enrollment increased: 60 → 80 participants · Trial sites expanded: 10 → 14 locations · 4 morev6 Show 7 more changesShow less
    • Primary and study completion pushed from Jul 2027 to Sep 2027
    • Enrollment increased: 60 → 80 participants
    • Trial sites expanded: 10 → 14 locations
    • Interventions: Gemcitabine 1000 mg/m^2 (Drug), Nab-paclitaxel 100 mg/m^2 (Drug), Relacorilant 150 mg once daily (QD) (Drug) to Gemcitabine (Drug), Nab-paclitaxel (Drug), Relacorilant (Drug)
    • Eligibility criteria expanded, about 11 words
    • Secondary endpoints: 11 to 14
    • Study description expanded, about 125 words

    See this version in full on ClinicalTrials.gov ↗

  5. Trial sites expanded: 7 → 10 locationsv5
Show 3 earlier versionsHide 3 earlier versions
  1. Study sites: 4 to 7v4
  2. Study sites: 1 to 4v3
  3. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date changed from estimate of Dec 2025 to Jan 27, 2026 · Secondary endpoints: details revised at 1 of 11 entriesv2 Show 3 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Dec 2025 to Jan 27, 2026
    • Secondary endpoints: details revised at 1 of 11 entries
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a 2-part, Phase 2 study to evaluate the safety, tolerability, dosing, pharmacokinetics (PK), and efficacy of relacorilant in combination with nab-paclitaxel and gemcitabine in chemotherapy-naïve patients with metastatic pancreatic adenocarcinoma (PDAC).
Trial Details
NCT Number NCT07259317
Lead Sponsor Corcept Therapeutics
Conditions Adenocarcinoma, Carcinoma, Pancreatic Ductal
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov